Profile data is unavailable for this security.
About the company
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
- Revenue in CHF (TTM)236.21m
- Net income in CHF72.66m
- Incorporated2002
- Employees180.00
- LocationBasilea Pharmaceutica AG AllschwilHegenheimermattweg 167bALLSCHWIL 4123SwitzerlandCHE
- Phone+41 616061111
- Fax+41 616061112
- Websitehttps://www.basilea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Formycon AG | 47.17m | -154.67m | 383.22m | 245.00 | -- | 1.03 | -- | 8.12 | -9.60 | -9.60 | 2.93 | 23.12 | 0.0613 | 31.72 | 1.91 | 207,112.00 | -20.09 | -1.47 | -21.17 | -1.58 | -0.9927 | 25.54 | -327.88 | -13.00 | 1.51 | -1.27 | 0.0244 | -- | -10.32 | 15.48 | -265.81 | -- | 96.87 | -- |
| Newron Pharmaceuticals SpA | 54.53m | 23.06m | 397.40m | 22.00 | 15.98 | 275.10 | 17.11 | 7.29 | 1.24 | 1.24 | 2.83 | 0.0722 | 1.39 | -- | 11.69 | 2,478,738.00 | 58.67 | -23.70 | 123.93 | -32.05 | 98.17 | 97.14 | 42.30 | -69.33 | -- | 8.56 | 0.9708 | -- | 467.41 | 48.83 | 197.65 | -- | -23.92 | -- |
| Philogen SpA | 71.72m | 41.83m | 575.48m | 193.00 | 18.99 | 6.91 | 12.64 | 8.02 | 1.14 | 1.14 | 1.96 | 3.13 | 0.5961 | 5.65 | 21.87 | 430,158.50 | 34.77 | 0.7964 | 40.11 | 0.8907 | 74.04 | 58.86 | 58.33 | 3.70 | 5.52 | -- | 0.0837 | -- | 219.91 | 42.46 | 835.14 | 100.38 | 10.46 | -- |
| Valneva SE | 163.92m | -93.08m | 680.63m | 700.00 | -- | 4.95 | -- | 4.15 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Basilea Pharmaceutica AG Allschwil | 236.21m | 72.66m | 759.26m | 180.00 | 10.89 | 6.79 | 10.18 | 3.21 | 5.23 | 5.23 | 17.03 | 8.40 | 1.08 | 1.66 | 10.57 | 1,440,305.00 | 33.21 | 7.08 | 39.78 | 11.18 | 81.04 | 82.50 | 30.76 | 9.96 | 5.67 | 31.61 | 0.4428 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
| Gubra A/S | 321.65m | 213.01m | 778.88m | 275.00 | -- | 5.25 | -- | 2.42 | -1.03 | -1.03 | 161.54 | 74.35 | 1.50 | -- | 68.31 | 11,174,780.00 | 99.21 | -- | 190.28 | -- | 3.52 | -- | 66.22 | -- | -- | -- | 0.0709 | -- | 29.63 | -- | 18.03 | -- | -- | -- |
| Nanobiotix SA | -12.80m | -47.05m | 917.22m | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Kuros Biosciences AG | 87.19m | -4.65m | 986.73m | 122.00 | -- | 16.22 | -- | 11.32 | -0.1218 | -0.1349 | 2.25 | 1.55 | 1.16 | 1.75 | 7.11 | 714,712.10 | -6.18 | -10.85 | -7.79 | -12.28 | 83.57 | 84.11 | -5.33 | -31.80 | 1.74 | -0.4702 | 0.0655 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| Inventiva SA | 12.40m | -283.41m | 994.81m | 84.00 | -- | -- | -- | 80.22 | -3.62 | -3.62 | 0.1543 | -0.064 | 0.1247 | -- | 2.35 | 124,871.60 | -284.55 | -80.43 | -555.93 | -122.98 | -- | -- | -2,282.71 | -989.96 | -- | -0.5041 | 1.18 | -- | -47.37 | 5.62 | -66.82 | -- | 19.61 | -- |
| Idorsia Ltd | 232.51m | -117.94m | 997.22m | 938.00 | -- | -- | -- | 4.29 | -0.6593 | -0.6593 | 1.06 | -4.88 | 0.4807 | 0.3793 | 796.27 | -- | -24.38 | -48.63 | -53.54 | -61.12 | 86.49 | -- | -50.72 | -526.39 | 0.8345 | -6.02 | 31.03 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
| Evotec SE | 689.08m | -144.84m | 1.00bn | 4.79k | -- | 1.37 | -- | 1.45 | -0.8955 | -0.8955 | 4.26 | 4.50 | 0.4019 | 20.15 | 5.17 | 156,687.00 | -8.45 | -2.40 | -10.41 | -2.87 | 10.82 | 21.49 | -21.02 | -6.78 | 2.03 | -2.54 | 0.3772 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Oxford BioMedica plc | 158.44m | -38.84m | 1.04bn | 900.00 | -- | 26.69 | -- | 6.58 | -0.3539 | -0.3539 | 1.46 | 0.3084 | 0.6556 | 5.25 | 4.25 | 175,626.00 | -16.95 | -20.23 | -23.87 | -25.48 | 44.12 | 49.36 | -25.85 | -45.03 | 1.67 | -4.81 | 0.7631 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
Data as of Feb 16 2026. Currency figures normalised to Basilea Pharmaceutica AG Allschwil's reporting currency: Swiss Franc CHF
22.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 18 Mar 2025 | 665.11k | 4.99% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 469.92k | 3.53% |
| Black Creek Investment Management, Inc.as of 31 Jul 2025 | 393.84k | 2.96% |
| BlackRock Fund Advisorsas of 28 Jan 2026 | 351.83k | 2.64% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Nov 2025 | 332.10k | 2.49% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 309.93k | 2.33% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 196.06k | 1.47% |
| DWS Investments (UK) Ltd.as of 05 Feb 2026 | 104.61k | 0.79% |
| Valiant Bank AGas of 31 Dec 2025 | 92.10k | 0.69% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 84.98k | 0.64% |
More ▼
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
